Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.97−0.27 (-2.40%)
Close on Nov 13, 2026Market cap $67.10MP/E –Yield –
Gossamer Bio operating margin
Operating margin is operating income as a percentage of revenue.
Gossamer Bio's operating margin for the twelve months ending Sep 30, 2026 was -140.0%. For fiscal 2025 it was -352.2%, against -52.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -352.2% | −300.0 |
| FY2024 | Dec 31, 2024 | -52.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 18.7% | +388.2 |
| Q2 FY2026 | Jun 30, 2026 | -282.2% | +55.2 |
| Q1 FY2026 | Mar 31, 2026 | -264.6% | +107.6 |
| Q4 FY2025 | Dec 31, 2025 | -333.6% | +51.6 |
| Q3 FY2025 | Sep 30, 2025 | -369.4% | −11.6 |
| Q2 FY2025 | Jun 30, 2025 | -337.4% | −391.8 |
| Q1 FY2025 | Mar 31, 2025 | -372.2% | – |
| Q4 FY2024 | Dec 31, 2024 | -385.2% | – |
| Q3 FY2024 | Sep 30, 2024 | -357.8% | – |
| Q2 FY2024 | Jun 30, 2024 | 54.3% | – |
See a number that looks wrong?